Näytä suppeat kuvailutiedot

dc.contributor.authorBah, Aissa
dc.contributor.authorNuotio, Ilpo
dc.contributor.authorPalomäki, Antti
dc.contributor.authorMustonen, Pirjo
dc.contributor.authorKiviniemi, Tuomas
dc.contributor.authorYlitalo, Antti
dc.contributor.authorHartikainen, Päivi
dc.contributor.authorAiraksinen, K. E. Juhani
dc.contributor.authorHartikainen, Juha E. K.
dc.date.accessioned2021-01-29T09:42:12Z
dc.date.available2021-01-29T09:42:12Z
dc.date.issued2021
dc.identifier.citationBah, A., Nuotio, I., Palomäki, A., Mustonen, P., Kiviniemi, T., Ylitalo, A., Hartikainen, P., Airaksinen, K. E. J., & Hartikainen, J. E. K. (2021). Inadequate oral anticoagulation with warfarin in women with cerebrovascular event and history of atrial fibrillation : the FibStroke study. <i>Annals of Medicine</i>, <i>53</i>(1), 287-294. <a href="https://doi.org/10.1080/07853890.2021.1875499" target="_blank">https://doi.org/10.1080/07853890.2021.1875499</a>
dc.identifier.otherCONVID_47817440
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/73886
dc.description.abstractBackground: Women with atrial fibrillation (AF) may be treated less actively with oral anticoagulation (OAC) than men. Patients and methods: We assessed sex differences in the implementation of stroke risk stratification with CHADS2 and CHA2DS2-VASc scores and reasons not to use OAC in 1747 AF patients suffering their first cerebrovascular event after the AF diagnosis. Results: Women were older and had more often a high stroke risk (CHADS2/CHA2DS2-VASc 2) than men (p < .001). On admission, 46.4% of women and 48.2% of men were on OAC with no sex difference (p ¼ .437). However, of patients without OAC, 74.4% of women and 49.5% of men should have been on OAC based on CHADS2/CHA2DS2-VASc 2 (p < .001). Conversely, 34.8% of men and 17.5% of women on OAC had a low or moderate risk (CHADS2/CHA2DS2-VASc 0–1, p < .001). A valid reason to omit OAC was reported in 38.6% of patients and less often in women (p < .001). Conclusions: OAC was underused in high-risk AF patients, particularly women, but prescribed often in men with low or moderate stroke risk. Reasons for omitting OAC treatment were poorly reported, particularly for women.en
dc.format.mimetypeapplication/pdf
dc.languageeng
dc.language.isoeng
dc.publisherTaylor & Francis
dc.relation.ispartofseriesAnnals of Medicine
dc.rightsCC BY 4.0
dc.subject.otheratrial fibrillation (AF)
dc.subject.otheroral anticoagulation (OAC)
dc.subject.otherCHADS2
dc.subject.otherCHA2DS2-VASc
dc.subject.othersex
dc.titleInadequate oral anticoagulation with warfarin in women with cerebrovascular event and history of atrial fibrillation : the FibStroke study
dc.typearticle
dc.identifier.urnURN:NBN:fi:jyu-202101291344
dc.contributor.laitosInformaatioteknologian tiedekuntafi
dc.contributor.laitosFaculty of Information Technologyen
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1
dc.description.reviewstatuspeerReviewed
dc.format.pagerange287-294
dc.relation.issn0785-3890
dc.relation.numberinseries1
dc.relation.volume53
dc.type.versionpublishedVersion
dc.rights.copyright© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
dc.rights.accesslevelopenAccessfi
dc.subject.ysohyytymisenestohoito
dc.subject.ysolääkemääräykset
dc.subject.ysoeteisvärinä
dc.subject.ysosydän- ja verisuonitaudit
dc.subject.ysosukupuolierot
dc.format.contentfulltext
jyx.subject.urihttp://www.yso.fi/onto/yso/p25978
jyx.subject.urihttp://www.yso.fi/onto/yso/p5840
jyx.subject.urihttp://www.yso.fi/onto/yso/p21917
jyx.subject.urihttp://www.yso.fi/onto/yso/p9886
jyx.subject.urihttp://www.yso.fi/onto/yso/p5290
dc.rights.urlhttps://creativecommons.org/licenses/by/4.0/
dc.relation.doi10.1080/07853890.2021.1875499
jyx.fundinginformationThis research is supported by The Finnish Foundation for Cardiovascular Research, Helsinki, Finland and the Clinical Research Fund (EVO) of Turku University Hospital, Turku, Finland.
dc.type.okmA1


Aineistoon kuuluvat tiedostot

Thumbnail

Aineisto kuuluu seuraaviin kokoelmiin

Näytä suppeat kuvailutiedot

CC BY 4.0
Ellei muuten mainita, aineiston lisenssi on CC BY 4.0